Your browser is no longer supported. Please, upgrade your browser.
Settings
AIMT Aimmune Therapeutics, Inc. daily Stock Chart
AIMT [NASD]
Aimmune Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.44 Insider Own0.90% Shs Outstand64.51M Perf Week-4.54%
Market Cap1.11B Forward P/E- EPS next Y-2.79 Insider Trans- Shs Float50.79M Perf Month-1.64%
Income-280.70M PEG- EPS next Q-1.07 Inst Own84.90% Short Float35.50% Perf Quarter20.66%
Sales0.60M P/S1843.75 EPS this Y-8.20% Inst Trans1.07% Short Ratio15.17 Perf Half Y-51.96%
Book/sh3.64 P/B4.62 EPS next Y35.40% ROA-95.80% Target Price- Perf Year-20.06%
Cash/sh5.45 P/C3.09 EPS next 5Y34.60% ROE-161.10% 52W Range10.09 - 37.00 Perf YTD-49.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-54.54% Beta0.96
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin55.30% 52W Low66.70% ATR1.03
Employees362 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)43.93 Volatility5.02% 6.05%
OptionableYes Debt/Eq0.55 EPS Q/Q-53.10% Profit Margin- Rel Volume0.57 Prev Close16.95
ShortableYes LT Debt/Eq0.55 EarningsMay 11 AMC Payout- Avg Volume1.19M Price16.82
Recom2.30 SMA20-6.59% SMA50-3.66% SMA200-28.12% Volume685,819 Change-0.80%
May-12-20Reiterated H.C. Wainwright Neutral $30 → $15
Mar-18-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-28-20Reiterated H.C. Wainwright Neutral $33 → $30
Feb-03-20Reiterated Wedbush Outperform $79 → $81
Dec-19-19Initiated H.C. Wainwright Neutral $33
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $30
Jul-12-19Resumed ROTH Capital Buy $45
May-21-19Resumed Credit Suisse Outperform $36 → $30
Dec-13-18Initiated Goldman Neutral $32
May-18-18Resumed Piper Jaffray Overweight
Feb-07-18Initiated RBC Capital Mkts Outperform $55
Dec-21-17Initiated Robert W. Baird Outperform $64
Nov-20-17Initiated ROTH Capital Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Mar-01-16Initiated Wedbush Outperform $42
Nov-17-15Reiterated Piper Jaffray Overweight $35 → $38
Aug-31-15Initiated Piper Jaffray Overweight $35
Aug-31-15Initiated Credit Suisse Outperform $44
Aug-31-15Initiated BofA/Merrill Buy $36
Jul-02-20 02:08PM  
12:01PM  
Jun-23-20 11:05AM  
Jun-08-20 11:50AM  
08:00AM  
08:00AM  
Jun-04-20 08:00AM  
Jun-01-20 08:00AM  
May-28-20 07:30AM  
May-19-20 06:18AM  
May-16-20 08:03AM  
May-12-20 08:00AM  
07:16AM  
12:01AM  
May-11-20 05:45PM  
04:05PM  
Apr-30-20 08:00AM  
Apr-08-20 08:00AM  
Apr-07-20 03:33PM  
Mar-22-20 08:06AM  
Mar-21-20 09:15AM  
Mar-17-20 10:40PM  
Mar-16-20 01:12PM  
08:00AM  
Mar-13-20 05:00PM  
Mar-11-20 06:25PM  
Feb-27-20 04:05PM  
07:35AM  
Feb-26-20 08:00AM  
Feb-25-20 08:00AM  
Feb-21-20 09:01AM  
Feb-20-20 05:43PM  
08:30AM  
Feb-19-20 10:13AM  
Feb-13-20 06:45AM  
Feb-12-20 05:50PM  
Feb-06-20 10:50AM  
Feb-05-20 02:19PM  
12:07PM  
11:52AM  
11:15AM  
10:28AM  
10:10AM  
08:58AM  
08:06AM  
08:01AM  
Feb-04-20 10:22AM  
Feb-03-20 04:16PM  
11:47AM  
11:11AM  
Feb-01-20 03:53PM  
Jan-31-20 06:13PM  
06:04PM  
05:20PM  
05:04PM  
Jan-20-20 02:18PM  
Jan-10-20 09:11AM  
Jan-09-20 05:56PM  
Jan-06-20 08:30AM  
Dec-30-19 09:24AM  
Dec-23-19 10:49AM  
Dec-08-19 06:24PM  
Nov-15-19 04:05PM  
Nov-14-19 10:03PM  
Nov-08-19 11:00AM  
11:00AM  
07:00AM  
07:00AM  
Nov-06-19 04:05PM  
08:21AM  
Nov-04-19 04:05PM  
Oct-31-19 07:00AM  
Oct-30-19 07:00AM  
Oct-28-19 10:59AM  
Oct-24-19 04:55PM  
Oct-07-19 06:48AM  
Oct-03-19 01:24AM  
Sep-26-19 07:00AM  
Sep-18-19 10:33AM  
Sep-16-19 04:19PM  
04:16PM  
01:18PM  
01:15PM  
Sep-13-19 08:00PM  
05:53PM  
05:10PM  
04:47PM  
10:30AM  
07:05AM  
06:50AM  
Sep-11-19 04:18PM  
Sep-10-19 04:37PM  
09:40AM  
Sep-09-19 10:23AM  
09:31AM  
Sep-05-19 10:12AM  
Aug-28-19 07:00AM  
Aug-26-19 08:54AM  
Aug-21-19 07:40AM  
07:00AM  
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ENRIGHT PATRICK GDirectorMar 18Buy11.0616,213179,34570,561Mar 19 05:03 PM
ENRIGHT PATRICK GDirectorMar 17Buy11.40100,0001,139,6506,113,134Mar 19 05:03 PM
ENRIGHT PATRICK GDirectorMar 17Buy11.508,787101,05154,348Mar 19 05:03 PM
Oxtoby AndrewChief Commercial OfficerMar 13Buy14.763,00044,26625,015Mar 17 04:51 PM
BJERKHOLT ERICChief Financial OfficerMar 12Buy15.101,00015,10042,967Mar 12 09:13 PM
Dallas Jayson Donald AlexanderPresident and CEOMar 10Buy18.742,66549,934123,283Mar 10 08:48 PM
BJERKHOLT ERICChief Financial OfficerMar 09Buy18.971,00018,97041,967Mar 10 08:47 PM
Societe des Produits Nestle S.10% OwnerFeb 07Buy131.091,525,634200,002,04912,727,113Apr 24 04:59 PM
Sheehy Douglas T.See RemarksJan 16Option Exercise12.954005,18046,068Jan 21 06:17 PM
Sheehy Douglas T.See RemarksJan 16Sale37.0040014,80045,668Jan 21 06:17 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 02Option Exercise19.6320,000392,60041,250Jan 03 08:41 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 02Sale35.0020,000700,03821,250Jan 03 08:41 PM
Sheehy Douglas T.See RemarksDec 26Option Exercise12.9510,000129,50055,668Dec 30 05:14 PM
Sheehy Douglas T.See RemarksDec 26Sale33.0310,000330,32245,668Dec 30 05:14 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 09Option Exercise11.4520,000229,00041,250Dec 11 05:50 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 09Sale30.0420,000600,71621,250Dec 11 05:50 PM
BJERKHOLT ERICChief Financial OfficerSep 18Buy22.571,55034,97733,574Sep 20 08:55 AM